RHOA and neoplasm: Additionally, large amounts of tumor tissue are needed to carry out a broad immunohistochemical panel, in situ hybridization (ISH) for EBV and complementary molecular tests, such as T-cell clonality assays by PCR and mutational profiling involving the RhoA gene and other epigenetic regulators by Sanger sequencing or next-generation sequencing (NGS) techniques.